Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests.
Vora
S
S
Division of Infectious Diseases, Geneva University Hospital, Switzerland.
Michon
C
C
Junet
C
C
Balavoine
J F
JF
Renold-Moynier
C
C
Yerly
S
S
Perrin
L
L
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006509:Hepatitis B / Q000150:complications / Q000201:enzymology / Q000503:physiopathology / Q000821:virology; D006526:Hepatitis C / Q000150:complications* / Q000201:enzymology / Q000503:physiopathology* / Q000821:virology; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008111:Liver Function Tests; D008297:Male; D019438:Ritonavir / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D019469:Indinavir; D019438:Ritonavir